CN107412720A - A kind of bitter gourd polypeptide compound plant medicine for treating diabetes and preparation method thereof - Google Patents
A kind of bitter gourd polypeptide compound plant medicine for treating diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN107412720A CN107412720A CN201710831992.6A CN201710831992A CN107412720A CN 107412720 A CN107412720 A CN 107412720A CN 201710831992 A CN201710831992 A CN 201710831992A CN 107412720 A CN107412720 A CN 107412720A
- Authority
- CN
- China
- Prior art keywords
- bitter gourd
- gourd polypeptide
- extract
- content
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of bitter gourd polypeptide compound plant medicine for treating diabetes and preparation method thereof, belong to diabetes medicament technical field.The autonomic drug includes 3~12 parts of 3~5 parts of bitter gourd polypeptide extracts, 2~4 parts of American ginseng extracts, 1~3 part of kudzu root extract, 1~3 part of Astragalus Root P.E, 0.0006~0.0008 part of chromium and auxiliary material in terms of parts by weight；Bitter gourd polypeptide protein content is more than 25% in bitter gourd polypeptide extract, and the content of total saposins is more than 15% in American ginseng extract, and the content of general flavone is more than 40% in kudzu root extract, and the content of astragalus polyose is more than 15% in Astragalus Root P.E.The autonomic drug can high efficiency extraction isolate and purify it is a large amount of there is the specified molecular weight for stablizing regulating and controlling blood sugar metabolic function and the natural activity bitter gourd polypeptides of sequence, with reference to traditional Chinese medicine unique formula, can significantly alleviate or eliminate other diabetic complications.Present invention also offers the preparation method of above-mentioned autonomic drug.
Description
Technical field
The present invention relates to diabetes medicament technical field, is answered in particular to a kind of bitter gourd polypeptide for treating diabetes
Square autonomic drug and preparation method thereof.
Background technology
As people's living standard improves constantly quick increasing is showed with social economy's fast development, China diabetic
Long situation, number of patients account for global diabetes patient's sum 1/3rd.China's diabetes morbidity is up to 9.6% at present, sugar
Patient is urinated more than 1.1 hundred million, and number of patients is also in cumulative year after year.The harm of diabetes is huge, with caused by diabetes
Diabetic complication also forms grave danger to the health and lives of patient.Diabetes Gu is referred to as quenching one's thirst, and refers to drink more, be more
Urine, eat and become thin, be tired more, urine sweet tea for principal character syndrome, laboratory examination its be mainly characterized by hyperglycaemia and glucose in urine.
It is due to that yin deficiency is scorching to quench one's thirst, caused by deficient five internal organs by drink more, more food, diuresis, body become thin characterized by illness.It is modern
The main reason for medical research shows, diabetes produce is that impaired islet cells, hypoinsulinism or body function are disorderly
Disorderly cause body to decline insulin sensitivity, cause diabetes so as to which the function of regulation blood glucose can not be played.
Momordica Curcurbitaceae balsam pear platymiscium, bitter is cold in nature, is a kind of medicine-food two-purpose vegetables.According to《Compendium of Materia Medica》And《Yunnan
Southern book on Chinese herbal medicine》Record, balsam pear has the function that clearing away heat and removing summer, nourishing blood and invigorating qi, kidney and spleen invigorating, nourishing liver for improving eyesight, hypoglycemic；Balsam pear contains
Trypsin inhibitor, the secreted protease out of cancer cell can be suppressed, prevent malignant tumour, and be also equipped with reducing blood lipid
With the effect of blood pressure.Chinese patent literature CN106974951A discloses the pharmaceutical composition for the treatment of diabetes, mainly by west
The compound such as medicine gliclazide and Chinese medicine ginseng, pseudo-ginseng and vitamin.Chinese patent literature CN107029093A discloses one kind
The Chinese medicine of diabetes is treated, 7 kinds of Chinese medicine materials are added and are decocted in water for oral dose.Chinese patent literature CN106975010A discloses one kind and controlled
The Chinese medicine composition of diabetes, the raw material containing 14 kinds of Chinese medicines and integration of drinking and medicinal herbs, including the root of kudzu vine are treated, the Radix Astragali and balsam pear etc. are straight by its
Connect crushing, sieving mixes, encapsulating capsule.Chinese patent literature CN107095975A disclose one kind treat diabetes prescription and its
Preparation method, 15 kinds of medicinal material cleanings are drained, pulverized after stir-frying, are directly taken after boiling water immersion.
Although it has been recognized that balsam pear is a kind of plant drug material for having effect of lowering blood sugar, and applied to sugar
Urinate in disease medicine, but there are problems that simultaneously：When above-mentioned document and the plant medicine about treating diabetes, greatly
After being taken after all kinds of formula materials are directly pulverized and sieved more or directly adding water to cook or crush plus be decocted in water for oral dose, without it is crucial into
The quality controllability and its content divided, it is impossible to ensure the stability and conspicuousness of product efficacy；Second, existing extracted using balsam pear
The hypoglycemic class medicine of thing, extract product are mostly based on saponin(e, are actually " Momordica charantial ", or anti-using all kinds of enzymolysis
Should or alkali carries acid is heavy obtains bitter gourd polypeptide protein, but its content is not high and the preparation time cycle is long or some step operation temperature
Degree is high, and the bitter gourd polypeptide of natural activity is the key component of Effective Regulation metabolism of blood glucose.Therefore, it is necessary to it is a kind of quality controllable and
The medicinal plants of the treatment diabetes of significant effect.
The content of the invention
It is an object of the invention to provide a kind of bitter gourd polypeptide compound plant medicine for treating diabetes, it can effectively be adjusted
Metabolism of blood glucose is controlled, there is the effect for the treatment of and preventing diabetes.
Another object of the present invention is to provide a kind of preparation method for the bitter gourd polypeptide compound plant medicine for treating diabetes,
It has technical matters stable, and quality controllability is strong, ensures the stability and conspicuousness of product nucleus, the production being prepared
Product have that blood sugar decreasing effect is good, stable effect, absorb Du Gao and it is convenient to take the advantages of.
What the present invention was realized in：
A kind of bitter gourd polypeptide compound plant medicine for treating diabetes, in terms of parts by weight, bitter gourd polypeptide compound plant pack
Contain：
3~5 parts of bitter gourd polypeptide extracts, the content of bitter gourd polypeptide albumen is more than 20% in bitter gourd polypeptide extract；
2~4 parts of American ginseng extracts, the content of total saposins is more than 15% in American ginseng extract；
1~3 part of kudzu root extract, the content of general flavone is more than 40% in kudzu root extract；
1~3 part of Astragalus Root P.E, the content of astragalus polyose is more than 15% in Astragalus Root P.E；
0.0006~0.0008 part of micro- chrome additive；And
3~12 parts of auxiliary materials.
Further, in present pre-ferred embodiments, in terms of parts by weight, it includes following raw material：
3.5~4 parts of bitter gourd polypeptide extracts, the content of bitter gourd polypeptide albumen is more than 25% in bitter gourd polypeptide extract；
2.5~3.5 parts of American ginseng extracts, the content of total saposins is more than 35% in American ginseng extract；
1.5~2.5 parts of kudzu root extracts, the content of general flavone is more than 60% in kudzu root extract；
1.5~2.5 parts of Astragalus Root P.Es, the content of astragalus polyose is more than 35% in Astragalus Root P.E；
0.0006~0.0008 part of micro- chrome additive；And
4~9 parts of auxiliary material.
Further, in present pre-ferred embodiments, the molecular weight of bitter gourd polypeptide albumen point in bitter gourd polypeptide extract
Cloth is 4.5k~68k, and content is more than 25%；Its middle-molecular-weihydroxyethyl is the content accounting example of 5.5~7kDa bitter gourd polypeptide fragment
For 18~25%.
Further, in present pre-ferred embodiments, American ginseng saponin extract is to extract to make by American Ginseng root
It is standby to obtain.
Further, in present pre-ferred embodiments, for the general flavone content of kudzu root extract more than 60%, it is total yellow
The content of Puerarin is more than 40% in ketone.
Further, in present pre-ferred embodiments, micro- chrome additive is chromium picolinate or yeast chromium.
Further, in present pre-ferred embodiments, auxiliary material include filler, binding agent, disintegrant, lubricant, point
At least one of powder；Auxiliary material is preferably Oligomeric manna sugar, pregelatinized starch, algal polysaccharides, D-sorbite, microcrystalline cellulose
One or more in element, PVPP.
Present invention also offers a kind of preparation method of bitter gourd polypeptide compound plant medicine, it comprises the following steps：
By 3~5 parts of bitter gourd polypeptide extracts, 2~4 parts of American ginseng extracts, 1~3 part of kudzu root extract, 1~3 part of Radix Astragali
Extract, 0.0006~0.0008 part of micro- chrome additive and 3~12 parts of auxiliary materials are well mixed, and are prepared into compound plant
Tablet；
Wherein, the preparation method of bitter gourd polypeptide extract includes：
The cleaning of balsam pear raw material, mashing is broken, with purification flooding balsam pear raw material, then centrifuge and remove slag, obtain centrifugate；
Centrifugate is filtered by the microfiltration membrane system that molecular cut off is 3 μm~0.1 μm, it is miscellaneous to remove macromolecular
Matter, obtain microfiltration membranes permeate；
Microfiltration membranes permeate is filtered by the rolling ultrafiltration membrane purification system that molecular cut off is 150kDa, obtained super
Filter membrane permeate；Milipore filter permeate is filtered through the rolling ultrafiltration membrane purification system that molecular cut off is 800Da again, obtained
To milipore filter trapped fluid；
Trapped fluid is concentrated by molecular cut off >=100Da rolling high pressure reverse osmosis membrane system, removes moisture
And part residual inorganic salts and small molecular weight impurity, obtain concentrate, solid content >=30% of concentrate；
Concentrate is dried, obtains the bitter gourd polypeptide extract powder that polypeptide protein content is not less than 25%.
Further, in present pre-ferred embodiments, rolling ultrafiltration membrane purification system is used in parallel using two films, mistake
Filter membrane is the filter membrane containing polysulfones or polyether sulfone materials, the operation temperature purified by roll-to-roll ultrafiltration membranous system for 15~
35 DEG C, operating pressure is 0.3~0.8MPa, and rolling high pressure reverse osmosis membrane concentration system is used using four film cascades, through pulleying
The operation temperature that formula high pressure reverse osmosis membrane is concentrated is 15~35 DEG C, and operating pressure is 3.5~5.5MPa.
Further, in present pre-ferred embodiments, it comprises the following steps：By bitter gourd polypeptide extract, American Ginseng
Extract, kudzu root extract, Astragalus Root P.E, trace element chromium and auxiliary material are well mixed rear drying and screening, through vibration grinding type
Ultramicro grinding obtains mixed powder below 50 μm of granularity；Using wet granulation process, by mixed powder and adhesive hydroxypropyl cellulose
HPC ethanol solution mixes softwood processed, 35~55 DEG C of drying 3~5 hours and crosses 40 eye mesh screens progress whole grain after granulation, measure contains
According to specification tabletting after amount, compound plant tablet is prepared into.
The beneficial effects of the invention are as follows：The bitter gourd polypeptide compound plant medicine for the treatment of diabetes provided by the invention, based on hardship
The hypoglycemic modern medicine study of melon and the diabetes of diabetes are theoretical, and high efficiency extraction, separation, purifying first largely has stable
The specified molecular weight of regulating and controlling blood sugar metabolic function and the natural activity bitter gourd polypeptide of sequence, its insulin receptor binding ability pole
By force, islet receptor protein signal path can be activated and recover damaged islet cells function；Selected in addition combined with traditional Chinese medicine unique formula
The trace element chromium of human insulin sensitiveness can be strengthened with American Ginseng, the root of kudzu vine, the Radix Astragali, and addition, through compounded plant
Thing tablet, quality controllable and combined therapy effect is obvious, and can significantly alleviate or eliminate other diabetic complications.This hair
The technical matters of the bitter gourd polypeptide compound plant medicine of the treatment diabetes of bright offer is stable, and quality controllability is strong, ensure that product
The stability and conspicuousness of nucleus, the product being prepared have that hypoglycemic effect is notable, stable effect, degree of absorbing
The advantages of high and convenient to take.
Brief description of the drawings
In order to illustrate the technical solution of the embodiments of the present invention more clearly, below by embodiment it is required use it is attached
Figure is briefly described, it will be appreciated that the following drawings illustrate only certain embodiments of the present invention, therefore be not construed as pair
The restriction of scope, for those of ordinary skill in the art, on the premise of not paying creative work, can also be according to this
A little accompanying drawings obtain other related accompanying drawings.
Fig. 1 is the SDS-PAGE electrophoresis of the polypeptide protein molecular weight distribution of bitter gourd polypeptide extract in the embodiment of the present invention
Figure.
Embodiment
, below will be in the embodiment of the present invention to make the purpose, technical scheme and advantage of the embodiment of the present invention clearer
Technical scheme be clearly and completely described.Unreceipted actual conditions person, builds according to normal condition or manufacturer in embodiment
The condition of view is carried out.Agents useful for same or the unreceipted production firm person of instrument, it is the conventional production that can be obtained by commercially available purchase
Product.
The embodiment of the present invention is specifically described below.
A kind of bitter gourd polypeptide compound plant medicine for treating diabetes is present embodiments provided, in terms of parts by weight, it is included
Following raw material：3~5 parts of bitter gourd polypeptide extracts, the content of its bitter gourd polypeptide albumen is more than 20%；2~4 parts of American Ginseng extractions
The content of thing, wherein total saposins is more than 15%；1~3 part of kudzu root extract, wherein the content of general flavone is more than 40%；1~
3 parts of Astragalus Root P.Es, wherein the content of astragalus polyose is more than 15%；0.0006~0.0008 part of micro- chrome additive；
And 3~12 parts of auxiliary materials；Preferably, raw material includes following composition：3.5~4 parts of bitter gourd polypeptide extracts, its bitter gourd polypeptide albumen
Content more than 25%；2.5~3.5 parts of American ginseng extracts, wherein the content of total saposins is more than 35%；1.5~2.5 parts
The content of kudzu root extract, wherein general flavone is more than 60%；1.5~2.5 parts of Astragalus Root P.Es, the wherein content of astragalus polyose
More than 35%；0.0006~0.0008 part of micro- chrome additive；And 4~9 parts of auxiliary material.Wherein, bitter gourd polypeptide extracts
The molecular weight distribution of bitter gourd polypeptide albumen is 4.5k~68k in thing, and for content more than 25%, its middle-molecular-weihydroxyethyl is 5.5~7kDa
Bitter gourd polypeptide fragment content accounting example be 18~25%；American ginseng saponin extract is to extract to prepare by American Ginseng root
Obtain, saponin(e total content is more than 40%；More than 60%, the content of wherein Puerarin exists the general flavone content of kudzu root extract
More than 40%；Chrome additive is preferably chromium picolinate or yeast chromium；Auxiliary material includes filler, binding agent, disintegrant, lubrication
At least one of agent, dispersant.Auxiliary material is preferably Oligomeric manna sugar, pregelatinized starch, algal polysaccharides, D-sorbite, crystallite
At least one of cellulose, PVPP.Preferably, auxiliary material include Oligomeric manna sugar, pregelatinized starch, algal polysaccharides,
At least two in D-sorbite, microcrystalline cellulose, PVPP.
Modern times of the bitter gourd polypeptide compound plant medicine based on balsam pear hypoglycemic for the treatment of diabetes provided in an embodiment of the present invention
The diabetes diabetes of medical research and traditional Chinese medicine is theoretical, is extracted from bitter gourd polypeptide extract, American ginseng extract, the root of kudzu vine
Thing, Astragalus Root P.E, chrome additive and auxiliary material is compound is prepared, can effectively adjust the blood glucose of human body, play significantly
Effect of lowering blood sugar.Wherein：
Bitter Melon P.E is the product for extracting to obtain from balsam pear, and the bitter gourd polypeptide contained in balsam pear has hypoglycemic, drop
The effect of blood fat, lifting body immunity, blood glucose and glycosuria, prevention and auxiliary treatment diabetes can be effectively reduced.Balsam pear
There is the specified molecular weight for stablizing regulating and controlling blood sugar metabolic function and the natural activity balsam pear of sequence containing a large amount of in polypeptide extract
Polypeptide protein, content are up to more than 25%, and for molecular weight distribution between 4.5k~68k, its middle-molecular-weihydroxyethyl is 5.5~7kDa hardship
The content accounting example of melon polypeptide fragment is 18~25%, and the Peptide of Protein size is close to insulin molecule amount, with insulin
The binding ability of acceptor is strong, can effectively activate insulin receptor protein signal path, recovers damaged islet cells function, and then
Blood sugar recovery effectively can be adjusted and controlled to normal level.
American ginseng extract is the product for extracting to obtain from American Ginseng by using solvent extraction method, American ginseng extract
In the American ginseng total saponins that contain can adjust the secretion of insulin and liver adrenal hormone, so as to enhance metabolism and right
Diabetes are prevented and treated, while it also has regulation blood pressure effect, can play vasodilator, improve cardiovascular
Can, suppress artery sclerosis the effect of.
Kudzu root extract is the product for extracting to obtain from the root of kudzu vine by using solvent extraction method, traditional Chinese medical science ancient documents and modern times
Clinical practice proves that the root of kudzu vine and its extract have the treatment of affirmative for treatment diabetes and its complication, angiocardiopathy etc.
Effect.Puerarin in kudzu root extract has adjustment blood glucose, blood fat, vasodilator, the superperformance of cardioprotection, while the root of kudzu vine
Element can also improve insulin sensitivity, mitigate insulin resistance, remove free radical, anti peroxidation of lipid, and then significantly improve sugar
Urinate the oxidation resistance in disease rat body.Kudzu root extract also contains a variety of flavones ingredients simultaneously, particularly its root of kudzu vine contained
Isoflavones can improve insulin sensitivity and have the function that hypoglycemic, while it is to chronic complicating diseases of diabetes such as diabetes
Nephrosis, diabetic cardiomyopathy, diabetic cerebrovascular disease, diabetic neuropathy, BDR etc.
There is improvement result.
Astragalus Root P.E is the product for extracting to obtain from the root of the Radix Astragali by using solvent extraction method, and Astragalus Root P.E has
There are strengthen immunity, antifatigue, liver protection.The astragalus polyose contained in Astragalus Root P.E has reducing blood lipid, that is, reduces courage
Sterol and triglycerides, the effect of increasing high density lipoprotein, can prevent and treat cardiovascular and cerebrovascular disease, such as Atherosclerosis
Change, coronary artery pathological changes, peripheral angiopathy and hyperlipidemia etc., and with reduction blood glucose, glycosylated hemoglobin and urine egg
White effect.
Chrome additive selects chromium picolinate or yeast chromium, and Cr3+ can strengthen insulin in chromium picolinate or yeast chromium
Effect, so as to influence the metabolism of carbohydrate, lipid, protein and nucleic acid etc., influence growth of animal breeding and resisting stress, disease-resistant
Ability, it can effectively improve bodily fuctions, activate insulin, adjust blood glucose.
The Oligomeric manna sugar selected in auxiliary material, pregelatinized starch, algal polysaccharides, D-sorbite, microcrystalline cellulose, crosslinking are poly-
Dimension ketone is respectively provided with not to be digested by human gastrointestinal tract, improves the effect of human body intestinal canal function, can not only be used as filler, bonding
Agent, disintegrant, lubricant, dispersant and raw material are prepared by mixing into the tablet of convenient absorption, additionally it is possible to prevent to reduce human body to sugar
Absorption, play the effect of assisting in reducing blood sugar.
Present invention also offers a kind of preparation method for the bitter gourd polypeptide compound plant medicine for treating diabetes, it includes following
Step：3~5 parts of bitter gourd polypeptide extracts, 2~4 parts of American ginseng extracts, 1~3 part of kudzu root extract, 1~3 part of Radix Astragali are carried
Take the carrier auxiliary material mixing such as thing, 0.0006~0.0008 part of chrome additive and 3~12 parts of fillers, dispersant and disintegrant equal
Even rear drying and screening, mixed powder below 10 μm of granularity is obtained through vibration grinding type ultramicro grinding；Using wet granulation process, medicine will be mixed
Powder mixes softwood processed with adhesive hydroxypropyl cellulose HPC ethanol solution, 35~55 DEG C of dryings 3~5 hours and mistake after granulation
40 eye mesh screens carry out whole grain, determine content after according to specification add lubricant tabletting, be prepared into compound plant tablet.
In the present embodiment, ginsenoside extract, Kudzu Flavonoids Extracts, astragalus polysaccharide extract, can be from city
Directly be commercially available on face, or can be also prepared using solvent extraction method, solvent extraction method include heating and refluxing extraction method,
Microwave concussion extraction method, decocting method, infusion process, percolation etc..Extraction solvent is water or ethanol water mixed solution system.
Wherein, the preparation method of bitter gourd polypeptide extract is：
S1, cleaning：From fresh bitter or dry balsam pear, bitter melon seed be used as balsam pear raw material, more select growth period it is longer, it is green
The fresh bitter that colour cast is yellow, balsam pear seed is fuller is as raw material.
Balsam pear cleaning method be：Balsam pear raw material is first cleaned through running water, then cleaned through electrolytic high-concentration ozone water,
Measuring Ozone Concentration in Water is cleaned up to 10~20mg/L, 150~450L/h of water-carrying capacity, further to remove agriculture residual pesticide, microorganism
Residual etc..
S2, mashing or crushing：20 mesh sieves were ground into by the fresh bitter mashing after cleaning or by dry balsam pear raw material
Coarse powder.
S3, extraction：Balsam pear raw material after mashing or crushing is poured into Ultrasonic Wave-Assisted Extraction tank, and adds 5~10 mass
Times, 38~52 DEG C of purified water, using buffer salt regulation system pH=6.8~7 be neutrality, carry out adverse current extraction 2~4 times, often
Secondary 30~60 minutes, yield was high.
S4, centrifugation are removed slag：Centrifuged, and removed slag using disc centrifuge or high speed tube centrifuge, obtain centrifugate.
S5, micro-filtration：Centrifugate is filtered by the microfiltration membrane system that molecular cut off is 3 μm~0.1 μm, removed big
Molecular impurity, obtain microfiltration membranes permeate.Molecular cut off is that 3 μm~0.1 μm of micro-filtrate membrane filtration system refers to microfiltration membranes
Cutoff performance is 3 μm~0.1 μm, such as：Molecular cut off is that 0.1 μm of microfiltration membrane system refers to that it can be retained more than 0.1 μ
M molecule, pass through the molecule no more than 0.1 μm.Microfiltration membranes permeate refers to can be by the liquid of microfiltration membrane system.
In the present embodiment, micro-filtrate membrane filtration system is used in parallel by three films, and filter membrane is organic tubular type, doughnut
Or ceramic micro filter film composition；The operation temperature filtered by microfiltration membrane system is 15~35 DEG C, operating pressure is 0.1~
0.5MPa。
S6, ultrafiltration：Rolling ultrafiltration membrane purification system by microfiltration membranes permeate by molecular cut off for 50~200kDa
Filtered, obtain milipore filter permeate.Molecular cut off is that 50~200kDa rolling ultrafiltration membrane purification system refers to rolling
The cutoff performance of milipore filter purification system is 50~200kDa, such as：The rolling ultrafiltration membrane that molecular cut off is 200kDa purifies
System refers to that it can be more than 200kDa molecule with molecular cut off, passes through molecule of the molecular weight no more than 200kDa.Ultrafiltration
Film permeate refers to the liquid by rolling ultrafiltration membrane purification system.
Milipore filter permeate was carried out by the rolling ultrafiltration membrane purification system that molecular cut off is 500~1000Da
Filter, obtains milipore filter trapped fluid.Molecular cut off is that 500~1000Da rolling ultrafiltration membrane purification system refers to rolling ultrafiltration membrane
The cutoff performance of purification system is 500~1000Da, such as：Molecular cut off is that 500Da rolling ultrafiltration membrane purification system is
500Da molecule can be more than with molecular cut off by referring to it, pass through molecule of the molecular weight no more than 500Da.Milipore filter trapped fluid
Refer to the liquid of rolling ultrafiltration membrane purification system retention.
In the present embodiment, rolling ultrafiltration membrane purification system is used in parallel using two films, and filter membrane is to contain (PS) polysulfones
Or the filter membrane of (PFS) polyether sulfone materials.The operation temperature purified by rolling ultrafiltration membrane purification system is 15~35 DEG C,
Operating pressure is 0.3~0.8MPa.
S7：Nanofiltration：Rolling high pressure counter-infiltration membrane system by milipore filter trapped fluid by molecular cut off for 100~150Da
System is concentrated, and is removed moisture and small molecular weight impurity, mainly part residual inorganic ion, is obtained concentrate, concentrate
Solid content >=30%.Molecular cut off is that 100~150Da rolling high pressure reverse osmosis membrane system refers to rolling high pressure reverse osmosis
The cutoff performance of membrane system is 100~150Da, such as：Molecular cut off is that 100Da rolling high pressure reverse osmosis membrane system is
100Da molecule can be more than with molecular cut off by referring to it, pass through molecule of the molecular weight no more than 100Da.Concentrate refers to roll up
The liquid of formula high pressure reverse osmosis membrane system retention.
In the present embodiment, rolling high pressure reverse osmosis membrane system is high pressure concentration film, specifically by polyamide compoiste material
Film is made.Rolling high pressure reverse osmosis membrane system concentration systems are used using four film cascades.By rolling high pressure counter-infiltration membrane system
The operation temperature concentrated of uniting is 15~35 DEG C, and operating pressure is 3.5~5.5MPa.
S8, drying：Concentrate is dried, drying means is vacuum freeze drying or low temperature spray drying, obtains hardship
Melon polypeptide protein content is not less than 25% Bitter Melon P.E powder, as bitter gourd polypeptide extract.
The bitter gourd polypeptide compound plant medicine for the treatment of diabetes provided in an embodiment of the present invention, wherein bitter gourd polypeptide extract are adopted
It is made with the membrane separation and purification technology preparation method of above-mentioned bitter gourd polypeptide.
The membrane separation and purification technology preparation technology of the bitter gourd polypeptide of the embodiment of the present invention, high efficiency extraction, separation, purifying have
The natural balsam pear polypeptide protein of blood glucose function is adjusted, exempts enzymolysis and high temperature enzyme deactivation step, it is with short production cycle, isolate and purify concentration
Temperature is low, the natural activity and its high content of the bitter melon protein polypeptide prepared has been effectively ensured, in bitter gourd polypeptide protein extract
The content of bitter gourd polypeptide albumen (molecular weight is 4.5k~68kDa) is at least above 25%.Not soybean protein-containing in extract product
The polypeptide protein in other non-balsam pear sources such as polypeptide.In addition, the embodiment of the present invention is using multi-level membrane separating and purifying skill
Art, normal-temperature operation, which is realized, efficiently separates purifying refining and concentrating, and production process low energy consumption, continuous operation are easy to clean.And plant
The conventional separation purifying technique of polypeptide protein uses the mode of gel-like molecular sieve column chromatography, not only cumbersome time-consuming, and
Gel filtration chromatography industrial amplification production cost is high, cleaning is cumbersome.
The feature and performance of the inventive method are described in further detail with reference to embodiments.
Embodiment 1
Embodiment 1 provides a kind of bitter gourd polypeptide compound plant medicine for treating diabetes, and its specific preparation process is as follows：
Prepare bitter gourd polypeptide extract：Longer from growth period, the fresh bitter that green is partially yellow, balsam pear seed is fuller is made
For raw material, balsam pear raw material is first cleaned through running water, then cleaned through electrolytic high-concentration ozone water, cleans Measuring Ozone Concentration in Water
15mg/L, water-carrying capacity 300L/h, remained with reducing agriculture residual pesticide and microorganism.Balsam pear raw material pulping after cleaning was broken into
The liquid material of 20 eye mesh screens.
The balsam pear raw material being beaten after crushing is poured into Ultrasonic Wave-Assisted Extraction tank, and adds 8 mass times, 50 DEG C of purification
Water, using buffer salt regulation system pH ≈ 7, the adverse current for carrying out ultrasonic wave added is extracted 3 times, every time 30 minutes.Using high speed tubular type
Centrifuge is centrifuged, and is removed slag, and obtains centrifugate.Centrifugate is passed through into the hollow fiber microfiltration membrane system that molecular cut off is 1 μm
System is filtered, and operation temperature is 30 DEG C, operating pressure 0.3MPa, obtains microfiltration membranes permeate.First by microfiltration membranes permeate point
Not Jing Guo molecular cut off be 200kDa rolling ultrafiltration membrane purification system filtered, operation temperature be 30 DEG C, operating pressure
For 0.8MPa, milipore filter permeate is obtained；Liquid is will transmit through again by the rolling ultrafiltration membrane purification system that molecular cut off is 800Da to enter
Row filtering, operation temperature are 30 DEG C, pressure 0.8MPa, obtain milipore filter trapped fluid.By milipore filter trapped fluid by retention point
Son amount is concentrated for 150Da rolling high pressure reverse osmosis membrane system, and operation temperature is 30 DEG C, operating pressure 4MPa, is obtained
The concentrate of solid content >=30%.Concentrate is dried by the way of vacuum freeze drying, obtains bitter gourd polypeptide
Protein extract, the content of its polypeptide protein is up to 27.5%.
By 4000g bitter gourd polypeptides protein extract, 3000g American ginseng extracts, 2000g kudzu root extracts, the 2000g Radixs Astragali
Extract, 0.6g chromium picolinates, 2000g microcrystalline celluloses, 2000g D-sorbites are well mixed rear drying and screening, through vibration
Mill formula ultramicro grinding obtains mixed powder；Mixed powder is mixed into softwood processed with adhesive hydroxypropyl cellulose HPC ethanol solution,
45 DEG C of dryings 3 hours and cross 40 eye mesh screens after granulation and carry out whole grain, determine after content according to specification tabletting, be prepared into compound plant medicine
Tablet.
Embodiment 2
Embodiment 2 provides a kind of bitter gourd polypeptide compound plant medicine for treating diabetes, and its specific preparation process is as follows：
Prepare bitter gourd polypeptide extract：Longer from growth period, the fresh bitter that green is partially yellow, balsam pear seed is fuller is made
For raw material, balsam pear raw material is first cleaned through running water, then cleaned through electrolytic high-concentration ozone water, Measuring Ozone Concentration in Water 20mg/
L, water-carrying capacity 450L/h, remained with reducing agriculture residual pesticide and microorganism.Balsam pear raw material pulping after cleaning was broken into 20 mesh
The liquid material of screen cloth.By be beaten it is broken after balsam pear raw material pour into Ultrasonic Wave-Assisted Extraction tank, and add 5 mass times, 38 DEG C
Purified water, using buffer salt regulation system pH ≈ 6.7, the adverse current for carrying out ultrasonic wave added is extracted 2 times, every time 60 minutes.Using
Disc centrifuge is centrifuged, and is removed slag, and obtains centrifugate.Centrifugate is passed through into organic tubular type that molecular cut off is 0.1 μm
Microfiltration membrane system is filtered, and operation temperature is 25 DEG C, pressure 0.5MPa, obtains microfiltration membranes permeate.First microfiltration membranes are passed through
Liquid is filtered by the rolling ultrafiltration membrane purification system that molecular cut off is 100kDa respectively, and operation temperature is 35 DEG C, pressure
For 0.6MPa, milipore filter permeate is obtained；Rolling ultrafiltration membrane purification system of the liquid by molecular cut off for 1000Da is will transmit through again
Filtered, operation temperature is 25 DEG C, pressure 0.8MPa, obtains milipore filter trapped fluid.By milipore filter trapped fluid by retaining
Molecular weight is that 100Da rolling high pressure reverse osmosis membrane system is concentrated, and operation temperature is 25 DEG C, operating pressure 5.0MPa,
Obtain the concentrate of solid content >=30%.Concentrate is dried by the way of low temperature spray drying, obtains balsam pear
Polypeptide protein extract, the content of its polypeptide protein is 25.8%.
By 3000g bitter gourd polypeptides protein extract, 2000g American ginseng extracts, 1500g kudzu root extracts, the 1000g Radixs Astragali
Done after extract, 0.7g yeast chromiums, 800g pregelatinized starch, 1000g microcrystalline celluloses and 600g PVPPs are well mixed
It is dry to sieve, obtain mixed powder through vibration grinding type ultramicro grinding；Mixed powder is mixed with hydroxypropyl cellulose HPC ethanol solution
Softwood processed, 40 DEG C of dryings 3.5 hours and cross screen cloth after granulation and carry out whole grain, determine after content according to specification tabletting, be prepared into compound
Plant tablet.
Embodiment 3
Embodiment 3 provides a kind of bitter gourd polypeptide compound plant medicine for treating diabetes, and its specific preparation process is as follows：
Prepare bitter gourd polypeptide extract：Raw material is used as from the drying balsam pear or balsam pear section that green is partially yellow, meat is full,
Balsam pear raw material was ground into the coarse powder of 20 mesh sieves.Balsam pear raw material after crushing is poured into Ultrasonic Wave-Assisted Extraction tank, and added
10 mass times, 52 DEG C of purified water, using buffer salt regulation system pH ≈ 6.8, the adverse current for carrying out ultrasonic assistant is extracted 2 times,
45 minutes every time.Centrifuged, and removed slag using high speed tube centrifuge, obtain centrifugate.Centrifugate is passed through into molecular cut off
Filtered for 0.2 μm of ceramic micro filter membranous system, operation temperature is 35 DEG C, pressure 0.5MPa, obtains microfiltration membranes permeate.First
Microfiltration membranes permeate is filtered by the rolling ultrafiltration membrane purification system that molecular cut off is 150kDa respectively, operation temperature
For 35 DEG C, pressure 0.5MPa, milipore filter permeate is obtained；Roll-to-roll ultrafiltration of the liquid by molecular cut off for 500Da is will transmit through again
Film purification system is filtered, and operation temperature is 35 DEG C, pressure 0.5MPa, obtains milipore filter trapped fluid.Milipore filter is retained
Liquid is concentrated by the rolling high pressure reverse osmosis membrane system that molecular cut off is 100Da, and operation temperature is 35 DEG C, and pressure is
4.5MPa, obtain the concentrate of solid content >=30%.Will be dense by the way of vacuum freeze drying or low temperature spray drying
Contracting liquid is dried, and obtains bitter gourd polypeptide protein extract, and the content of its polypeptide protein is up to 28.6%.
By 5000g bitter gourd polypeptides protein extract, 4000g American ginseng extracts, 3000g kudzu root extracts, the 3000g Radixs Astragali
Done after extract, 0.8g chrome additives, 1500g Oligomeric manna sugars, 1500g microcrystalline celluloses, 800g D-sorbites are well mixed
It is dry to sieve, obtain mixed powder through vibration grinding type ultramicro grinding；Mixed powder is mixed with hydroxypropyl cellulose HPC ethanol solution
Softwood processed, 50 DEG C of dryings 3 hours and cross 40 eye mesh screens after granulation and carry out whole grain, determine after content according to specification tabletting, be prepared into multiple
Square plant tablet.
The molecular weight of bitter gourd polypeptide albumen in bitter gourd polypeptide extract in embodiment is detected：
The polypeptide protein molecular weight distribution in bitter gourd polypeptide protein extract is detected using SDS-PAGE analytic approach,
Fig. 1 is the PAGE electrophoretograms detected.
By Fig. 1 it can be found that：The bitter gourd polypeptide albumen of the bitter gourd polypeptide extract obtained according to preparation method of the present invention, point
For the content accounting for the bitter gourd polypeptide that son amount is 5.5~7kDa more than 20%, the Peptide of Protein is Effective Regulation blood glucose generation
The key function composition thanked, close to insulin molecule amount.Therefore, the balsam pear obtained according to the technical matters of the embodiment of the present invention is more
Contain a large amount of natural activity bitter gourd polypeptide albumen with regulation blood glucose function in peptide extract.
Evaluating drug effect is carried out to the bitter gourd polypeptide compound plant medicine that embodiment 1, embodiment 2 and embodiment 3 provide below：
First, influence of the bitter gourd polypeptide compound plant medicine to rat blood sugar value.
From the rat (150g ± 2g) of health, rat is randomly assigned into 4 groups, used by 60mg/kg/day dosage
Twice, diabetes rat is made in Streptozotocin injection rat, then daily Example 1, embodiment 2 and embodiment 3 respectively
In tablet crush, add pure water to prepare gavage liquid, the same day prepares, and once, gavage capacity is 0.2g/kg to daily oral gavage
Body weight, continuously gives tested material 45d, the pure water of the daily gavage equivalent of control group, and last day is 2 small before gavage and after gavage
When detect each group rat model blood glucose value and glycosylated hemoglobin, as a result shown in following Tables 1 and 2.
Influence of the bitter gourd polypeptide compound plant medicine of table 1 to rat blood sugar value
From table 1, each group diabetic animal models blood sugar test value there was no significant difference (P before experiment>0.05).With it is right
To be compared according to group, each dosage group rat fasting blood-glucose value recovers normal, and blood glucose decreasing value and blood glucose reduce percentage and greatly improved,
Show that the product has the function that to reduce diabetic model rats blood glucose.
2nd, influence of the bitter gourd polypeptide compound plant medicine to rat glycosylated hemoglobin.
Animal protocols as above 1.1；Experimental result is shown in Table 2
Influence of the bitter gourd polypeptide compound plant medicine of table 2 to rat glycosylated hemoglobin
From table 2, each group diabetic animal glycosylated hemoglobin detected value there was no significant difference (P before experiment>0.05).
Compared with control group, each embodiment group rat glycosylated hemoglobin declines to a great extent, and significant difference (P is presented<0.05),
Illustrate that the product has the function that to reduce diabetic model rats glycosylated hemoglobin.
3rd, crowd's trial state of the bitter gourd polypeptide compound plant medicine of diabetes is treated.
1st, diabetic.Examination takes the diabetic 90 of bitter gourd polypeptide compound plant medicine, wherein male 45, women
45, max age 72 years old, minimal ages 35 years old, average age 53.5 years old.
2nd, diagnostic criteria.(1) empty stomach whole blood blood glucose >=6.7 mM/l, plasma glucose >=7.8 mM/l, 2 weights
It is diabetes that repetition measurement, which is determined diagnosable,.When fasting blood-glucose significantly increases, it is not necessary to carry out other inspections, you can be diagnosed as diabetes.(2)
When empty stomach whole blood blood glucose is more than 5.6 mM/ls, plasma glucose should do carbohydrate tolerance test more than 6.4 mM/ls.If
If there is obvious diabetic symptom, postprandial 2 hours blood sugar detections should be first done.(3) normal person postprandial 2 hours whole blood blood glucose not
More than 5.6 mM/ls, plasma glucose is no more than 6.4 mM/ls.If whole blood blood glucose >=7.8 mM of postprandial 2 hours/
Rise, during plasma glucose >=8.9 mM/l, diagnosable is diabetes.
3rd, treatment method.The bitter gourd polypeptide compound plant medicine of present invention treatment treatment diabetes (presses the method system of embodiment 1
It is standby), daily 2-3 times, 1 tablet once, and warm water is swallowed, and 1 course for the treatment of 1 month, takes 3 courses for the treatment of.
4th, criterion of therapeutical effect.(1) significantly：Fasting blood-glucose and postprandial blood sugar drop to normal range (NR) or fasting blood-glucose and postprandial blood
Sugared 2 hours blood glucose values decrease beyond 40% before treatment, before glycosylated hemoglobin value is down to normal or drop-out value more than treatment
30%.Complication at least more than two organ functions have clear improvement, and irreversible functional lesion makes moderate progress (such as eyesight).
(2) effectively：Fasting blood-glucose and postprandial blood sugar decrease beyond 20% before treatment, but not up to effective standard for 2 hours.HbAle
Protein value decrease beyond 10% before treatment, but not up to effective standard.At least one organ function of complication is restored
(such as four limbs consciousness function).(3) fully recover：The fluctuation in 2 hours of fasting blood-glucose and postprandial blood sugar is in normal range (NR), glycosylated hemoglobin
It is worth back to normal, the multiple organ dysfunction such as the heart, brain, blood vessel is restored or significantly improved, and irreversible function infringement makes moderate progress, extremely
It is few not recurred more than half a year.(4) it is invalid：Pretherapy and post-treatment clinical symptoms, which have no, to be clearly better, and fasting blood-glucose and postprandial blood sugar 2 are small
When decline unobvious, glycosylated hemoglobin value, which declines, is not up to effective standard.
5th, treatment results.Examination takes the diabetic 90 of bitter gourd polypeptide compound plant medicine, the people of male 45, the people of women 45,
Max age 72 years old, minimal ages 35 years old, average age 53.5 years old.Effective 24 people, effective 10 people, fully recover 54 people, invalid 2 people,
Total effective 97.8%.
In summary, the preparation method energy of the bitter gourd polypeptide compound plant medicine for the treatment of diabetes provided in an embodiment of the present invention
The pharmaceutical composition of Effective Regulation metabolism of blood glucose function is enough prepared.The bitter gourd polypeptide compound plant medicine energy of the treatment diabetes
Enough recover damaged islet cells function, reduce blood glucose value and stable effect, there is the effect for the treatment of and preventing diabetes.
The preferred embodiments of the present invention are the foregoing is only, are not intended to limit the invention, for the skill of this area
For art personnel, the present invention can have various modifications and variations.Within the spirit and principles of the invention, that is made any repaiies
Change, equivalent substitution, improvement etc., should be included in the scope of the protection.
Claims (10)
- A kind of 1. bitter gourd polypeptide compound plant medicine for treating diabetes, it is characterised in that in terms of parts by weight, the bitter gourd polypeptide Compound plant pack contains：3~5 parts of bitter gourd polypeptide extracts, the content of bitter gourd polypeptide albumen is more than 20% in the bitter gourd polypeptide extract；2~4 parts of American ginseng extracts, the content of total saposins is more than 15% in the American ginseng extract；1~3 part of kudzu root extract, the content of general flavone is more than 40% in the kudzu root extract；1~3 part of Astragalus Root P.E, the content of astragalus polyose is more than 15% in the Astragalus Root P.E；0.0006~0.0008 part of micro- chrome additive；And3~12 parts of auxiliary materials.
- 2. the bitter gourd polypeptide compound plant medicine for the treatment of diabetes according to claim 1, it is characterised in that with parts by weight Meter, it includes following raw material：3.5~4 parts of bitter gourd polypeptide extracts, in the bitter gourd polypeptide extract content of bitter gourd polypeptide albumen 25% with On；2.5~3.5 parts of American ginseng extracts, the content of total saposins is more than 35% in the American ginseng extract；1.5~2.5 parts of kudzu root extracts, the content of general flavone is more than 60% in the kudzu root extract；1.5~2.5 parts of Astragalus Root P.Es, the content of astragalus polyose is more than 35% in the Astragalus Root P.E；0.0006~0.0008 part of micro- chrome additive；And4~9 parts of the auxiliary material.
- 3. the bitter gourd polypeptide compound plant medicine for the treatment of diabetes according to claim 1 or 2, it is characterised in that the hardship The molecular weight distribution of bitter gourd polypeptide albumen is 4.5k~68k in melon polypeptide extract, and content is more than 25%；Its middle-molecular-weihydroxyethyl is The content accounting example of 5.5~7kDa bitter gourd polypeptide fragment is 18~25%.
- 4. the bitter gourd polypeptide compound plant medicine for the treatment of diabetes according to claim 1 or 2, it is characterised in that the west Radix Panacis Quinquefolii saponin extract is prepared by the extraction of American Ginseng root.
- 5. the bitter gourd polypeptide compound plant medicine for the treatment of diabetes according to claim 1 or 2, it is characterised in that the Pueraria lobota The general flavone content of root extract is more than 60%, and the content of Puerarin is more than 40% in its general flavone.
- 6. the bitter gourd polypeptide compound plant medicine for the treatment of diabetes according to claim 1 or 2, it is characterised in that described micro- Secondary element chrome additive is chromium picolinate or yeast chromium.
- 7. the bitter gourd polypeptide compound plant medicine for the treatment of diabetes according to claim 1 or 2, it is characterised in that described auxiliary Material includes at least one of filler, binding agent, disintegrant, lubricant, dispersant；The auxiliary material is preferably oligomeric sweet dew One or more in sugar, pregelatinized starch, algal polysaccharides, D-sorbite, microcrystalline cellulose, PVPP.
- 8. a kind of preparation method of bitter gourd polypeptide compound plant medicine, it is characterised in that it comprises the following steps：By 3~5 parts of bitter gourd polypeptide extracts, 2~4 parts of American ginseng extracts, 1~3 part of kudzu root extract, 1~3 part of astragalus extraction Thing, 0.0006~0.0008 part of micro- chrome additive and 3~12 parts of auxiliary materials are well mixed, and are prepared into compound plant tablet Agent；Wherein, the preparation method of the bitter gourd polypeptide extract includes：The cleaning of balsam pear raw material, mashing is broken, with purification flooding balsam pear raw material, then centrifuge and remove slag, obtain centrifugate；The centrifugate is filtered by the microfiltration membrane system that molecular cut off is 3 μm~0.1 μm, it is miscellaneous to remove macromolecular Matter, obtain microfiltration membranes permeate；The microfiltration membranes permeate is filtered by the rolling ultrafiltration membrane purification system that molecular cut off is 150kDa, obtained super Filter membrane permeate；The milipore filter permeate was carried out through the rolling ultrafiltration membrane purification system that molecular cut off is 800Da again Filter, obtains milipore filter trapped fluid；The trapped fluid is concentrated by molecular cut off >=100Da rolling high pressure reverse osmosis membrane system, removes moisture And part residual inorganic salts and small molecular weight impurity, obtain concentrate, solid content >=30% of the concentrate；The concentrate is dried, obtains the bitter gourd polypeptide extract powder that polypeptide protein content is not less than 25%.
- 9. the preparation method of bitter gourd polypeptide compound plant medicine according to claim 8, it is characterised in that the roll-to-roll ultrafiltration Film purification system is used in parallel using two films, and filter membrane is the filter membrane containing polysulfones or polyether sulfone materials, is surpassed by rolling The operation temperature that filter membrane system is purified is 15~35 DEG C, and operating pressure is 0.3~0.8MPa, the rolling high pressure counter-infiltration Film concentration systems are used using four film cascades, and the operation temperature concentrated by rolling high pressure reverse osmosis membrane is 15~35 DEG C, operating pressure is 3.5~5.5MPa.
- 10. the preparation method of bitter gourd polypeptide compound plant medicine according to claim 8, it is characterised in that it includes following Step：By the bitter gourd polypeptide extract, American ginseng extract, the kudzu root extract, the Astragalus Root P.E, described Trace element chromium and the well mixed rear drying and screening of the auxiliary material, mixing below 50 μm of granularity is obtained through vibration grinding type ultramicro grinding Medicinal powder；Using wet granulation process, it is soft that the mixed powder is mixed with adhesive hydroxypropyl cellulose HPC ethanol solution to system Material, 35~55 DEG C of dryings 3~5 hours and cross 40 eye mesh screens after granulation and carry out whole grain, determine after content according to specification tabletting, be prepared into Compound plant tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710831992.6A CN107412720A (en) | 2017-09-15 | 2017-09-15 | A kind of bitter gourd polypeptide compound plant medicine for treating diabetes and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710831992.6A CN107412720A (en) | 2017-09-15 | 2017-09-15 | A kind of bitter gourd polypeptide compound plant medicine for treating diabetes and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107412720A true CN107412720A (en) | 2017-12-01 |
Family
ID=60432594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710831992.6A Pending CN107412720A (en) | 2017-09-15 | 2017-09-15 | A kind of bitter gourd polypeptide compound plant medicine for treating diabetes and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107412720A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108114268A (en) * | 2018-01-03 | 2018-06-05 | 吴宝娥 | A kind of Chinese medicine composition for reducing blood glucose, preparation and preparation method and application |
| CN108420065A (en) * | 2018-03-30 | 2018-08-21 | 山东诺贝肽生物科技有限公司 | A kind of antihypelipidemic product rich in bitter gourd polypeptide |
| CN110624091A (en) * | 2019-10-25 | 2019-12-31 | 李玉保 | Ginkgo leaf compound polyphenol capsule with lipid-lowering and thrombolytic effects and preparation method thereof |
| CN110694046A (en) * | 2019-10-25 | 2020-01-17 | 国众兴合生物医药科技有限公司 | Plant medicine for treating diabetes and hyperlipemia and its prepn |
| CN110755598A (en) * | 2019-10-25 | 2020-02-07 | 李玉保 | Compound bitter gourd peptide oral medicine for activating insulin and treating diabetes and preparation method thereof |
| CN110772630A (en) * | 2019-10-25 | 2020-02-11 | 运鸿集团股份有限公司 | Compound bitter gourd peptide oral liquid for activating insulin receptor and regulating blood sugar and preparation method thereof |
| CN110801024A (en) * | 2019-10-25 | 2020-02-18 | 运鸿集团股份有限公司 | Polysaccharide composite polypeptide for reducing blood sugar, blood fat and glycosylated hemoglobin and preparation method thereof |
| CN111171112A (en) * | 2020-03-17 | 2020-05-19 | 广西壮族自治区农业科学院 | Enzymatic extraction method of bitter melon seed protein |
| CN112587648A (en) * | 2020-02-05 | 2021-04-02 | 河北康平健康产业有限责任公司 | Bitter gourd peptide composition for preventing and treating diabetes and preparation method thereof |
| CN113812636A (en) * | 2020-06-18 | 2021-12-21 | 陈信行 | Humic acid-bitter gourd peptide compound and its preparing process |
| CN114250178A (en) * | 2021-12-21 | 2022-03-29 | 泰伦特生物工程股份有限公司 | Microbial preparation for removing organic matters on metal surface and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127338A (en) * | 1997-04-01 | 2000-10-03 | Calyx Therapeutics, Inc. | Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes |
| CN1418889A (en) * | 2002-09-23 | 2003-05-21 | 北海海玉农业开发有限责任公司 | Momordi glucose-reducing polypeptide |
| CN101985644A (en) * | 2010-10-25 | 2011-03-16 | 邹远东 | Momordica charantia polypeptide, preparation method and application thereof |
| CN102652828A (en) * | 2011-03-03 | 2012-09-05 | 王�锋 | Polypeptide-k buccal tablet |
| CN102948749A (en) * | 2012-11-23 | 2013-03-06 | 乔德京 | American ginseng and omei mountain kudzuvine capsule |
| CN103989168A (en) * | 2014-05-23 | 2014-08-20 | 天津大学 | Composition capable of lowering sugar and fat |
| CN104840938A (en) * | 2015-06-09 | 2015-08-19 | 郑相国 | Chinese patent medicine for treating diabetes |
-
2017
- 2017-09-15 CN CN201710831992.6A patent/CN107412720A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127338A (en) * | 1997-04-01 | 2000-10-03 | Calyx Therapeutics, Inc. | Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes |
| CN1418889A (en) * | 2002-09-23 | 2003-05-21 | 北海海玉农业开发有限责任公司 | Momordi glucose-reducing polypeptide |
| CN101985644A (en) * | 2010-10-25 | 2011-03-16 | 邹远东 | Momordica charantia polypeptide, preparation method and application thereof |
| CN102652828A (en) * | 2011-03-03 | 2012-09-05 | 王�锋 | Polypeptide-k buccal tablet |
| CN102948749A (en) * | 2012-11-23 | 2013-03-06 | 乔德京 | American ginseng and omei mountain kudzuvine capsule |
| CN103989168A (en) * | 2014-05-23 | 2014-08-20 | 天津大学 | Composition capable of lowering sugar and fat |
| CN104840938A (en) * | 2015-06-09 | 2015-08-19 | 郑相国 | Chinese patent medicine for treating diabetes |
Non-Patent Citations (3)
| Title |
|---|
| 张虎成等: "《现代生物技术理论及应用研究》", 31 January 2016, 中国水利水电出版社 * |
| 牛勃主编: "《现代生物学技术进展》", 31 May 2007, 山西人民出版社 * |
| 盛清凯: "苦瓜降糖多肽-P的分离纯化及降糖机理研究", 《中国博士学位论文全文数据库 工程科技I辑》 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108114268A (en) * | 2018-01-03 | 2018-06-05 | 吴宝娥 | A kind of Chinese medicine composition for reducing blood glucose, preparation and preparation method and application |
| CN108420065A (en) * | 2018-03-30 | 2018-08-21 | 山东诺贝肽生物科技有限公司 | A kind of antihypelipidemic product rich in bitter gourd polypeptide |
| CN110801024A (en) * | 2019-10-25 | 2020-02-18 | 运鸿集团股份有限公司 | Polysaccharide composite polypeptide for reducing blood sugar, blood fat and glycosylated hemoglobin and preparation method thereof |
| CN110694046A (en) * | 2019-10-25 | 2020-01-17 | 国众兴合生物医药科技有限公司 | Plant medicine for treating diabetes and hyperlipemia and its prepn |
| CN110755598A (en) * | 2019-10-25 | 2020-02-07 | 李玉保 | Compound bitter gourd peptide oral medicine for activating insulin and treating diabetes and preparation method thereof |
| CN110772630A (en) * | 2019-10-25 | 2020-02-11 | 运鸿集团股份有限公司 | Compound bitter gourd peptide oral liquid for activating insulin receptor and regulating blood sugar and preparation method thereof |
| CN110624091A (en) * | 2019-10-25 | 2019-12-31 | 李玉保 | Ginkgo leaf compound polyphenol capsule with lipid-lowering and thrombolytic effects and preparation method thereof |
| GB2608697B (en) * | 2019-10-25 | 2023-11-15 | China Yunhong Holdings Co Ltd | Polysaccharide-peptide complex for lowering blood sugar, blood lipid and glycosylated hemoglobin levels, and preparation method |
| GB2607449B (en) * | 2019-10-25 | 2023-12-27 | Li Yubao | Activated insulin, compound Momordica charantia peptide oral medicine for treatment of diabetes, and preparation method |
| CN112587648A (en) * | 2020-02-05 | 2021-04-02 | 河北康平健康产业有限责任公司 | Bitter gourd peptide composition for preventing and treating diabetes and preparation method thereof |
| CN111171112A (en) * | 2020-03-17 | 2020-05-19 | 广西壮族自治区农业科学院 | Enzymatic extraction method of bitter melon seed protein |
| CN113812636A (en) * | 2020-06-18 | 2021-12-21 | 陈信行 | Humic acid-bitter gourd peptide compound and its preparing process |
| CN114250178A (en) * | 2021-12-21 | 2022-03-29 | 泰伦特生物工程股份有限公司 | Microbial preparation for removing organic matters on metal surface and preparation method thereof |
| CN114250178B (en) * | 2021-12-21 | 2024-01-23 | 泰伦特生物工程股份有限公司 | Microbial preparation for removing organic matters on metal surface and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107412720A (en) | A kind of bitter gourd polypeptide compound plant medicine for treating diabetes and preparation method thereof | |
| CN107412721B (en) | Blood sugar-reducing bitter gourd polypeptide compound capsule and preparation method thereof | |
| CN104621296B (en) | It is a kind of that there is regulation blood fat, blood glucose, the Chinese traditional medicine composition tea beverage of blood pressure function | |
| CN110051726A (en) | The preparation method and application of general flavone and total starches in a kind of Qingqian Willow leaf | |
| CN107581620A (en) | A kind of compound lozenge of hypoglycemic bitter gourd polypeptide and preparation method thereof | |
| CN107439936A (en) | Polypeptide Diatotherapeutic flour of diabetic and preparation method thereof | |
| CN107455663A (en) | Polypeptide dietotherapy noodles of diabetic and preparation method thereof | |
| CN102113534B (en) | Moon cake with function of treating diabetes and preparation method thereof | |
| CN109692194B (en) | Compound traditional Chinese medicine composition for treating diabetic nephropathy and preparation method and application thereof | |
| CN107468744A (en) | A kind of new method, bitter gourd polypeptide protein extract and its application of whole temperature production bitter gourd polypeptide protein extract | |
| CN105943569A (en) | Method for extracting effective ingredients of green plums | |
| CN108686113A (en) | A kind of composition and preparation method thereof for alleviating three high diseases shape | |
| CN107594541A (en) | A kind of the membrane separation and purification technology technique for preparing bitter gourd polypeptide albumen, bitter gourd polypeptide protein extract and its application | |
| CN107495020A (en) | A kind of suitable polypeptide beverage water of diabetic population and its preparation technology | |
| CN106177434A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN104524214B (en) | Treat the Chinese medicine composition and its Chinese medicine preparation, preparation method and application of digestive tract ulcer | |
| CN103120732A (en) | Chinese medicinal composition for treating jaundice and preparation method thereof | |
| CN109512951A (en) | A kind of Chinese medicine that preventing and treating Alzheimer disease-desert cistanche joins sweet rhizome of chuanxiong Yizhi Decoction and preparation method thereof | |
| CN108815391A (en) | A kind of preparation process of double Herba Dendrobii extracts of liver damage protection function | |
| CN108041558A (en) | A kind of health soy sauce and preparation method thereof | |
| CN107812115A (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN103893286B (en) | It is a kind of to treat Chinese medicine preparation of chronic renal disease and preparation method thereof | |
| CN103585495B (en) | Capsule for treating diabetic kidney damage | |
| CN106344829A (en) | Traditional Chinese medicine composition and production method thereof | |
| CN107510836A (en) | A kind of bitter gourd polypeptide pharmaceutical composition for treating diabetic ulcer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 435400 Hubei province Huanggang city Wuxue city Wuxue Street Xing Village 170 Applicant after: Li Yubao Applicant after: He Jingren Applicant after: Yunhong Group Co.,Ltd. Address before: No. 170, Xingjia village, Wuxue street, Huanggang, Hubei Province Applicant before: Li Yubao Applicant before: He Jingren Applicant before: HUBEI YUNHONG ENERGY GROUP Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171201 |